News: MSB Mesoblast Posts Qtrly Loss Attributable Of US$25 Mln, page-5

I suspect there will be a tree shake today of sorts. Always seems to be after the reporting of financials.

I am not a finance expert, but I do note that most operating expenses are down with the exception of manufacturing, which is up $9 mil. My reading of that is as a bullish sign from the company. The other item that is up is the financing expenses, but I see that as a necessary evil for the next 12 months until revenue starts rolling in. If we're prepared to ride it out, better than diluting with a cap raise. In any event 9 months of net cash outflow was just under 39 mil with 70 mil in cash reserve. As Bennybeenymay says, that may gives us a decent runway.

The one thing I would like to point out (other than the obvious 'advanced' discussion re: partnership) is the timeline for FDA meeting for Revascor in regards to End Stage Heart Failure. Previously identified as a 1HCY19 milestone, but the timing has been removed and the wording is to 'schedule' not 'scheduled'. That is probably the only disappointment for me.

DYOR.